Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany

Abstract excerpt

Background Non-small-cell lung cancer patients with BRAF V600E mutations benefit from targeted and (chemo-)immune therapy. However, treatment of BRAF non-V600E mutations poses substantial challenges due to biological heterogeneity, different clinicogenomic features and limited therapy outcome data. Materials and methods We conducted a retrospective analysis of BRAF non-V600E mutation patients in the national...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Lung Cancer Treatments and Mutations
• Share to Melanoma and MAPK Pathways